- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06850909
Evaluating the Influence of 3D Culture Dish Design on Preimplantation Genetic Development in Sibling Oocytes: a Randomized Trial
February 26, 2025 updated by: Eman Hasanen, Ganin Fertility Center
Evaluating the Influence of 3D Culture Dish Design on Preimplantation Genetic Development in Sibling Oocytes: A Randomized Trial
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
The configuration of culture dishes plays a crucial role in preimplantation embryo development by influencing key culture conditions such as media distribution, oxygen exchange, and embryo spacing, all of which directly impact embryonic growth, fertilization, blastocyst formation, and overall blastocyst quality.
Traditional 2D culture dishes provide a flat surface for embryo development, whereas 3D culture dishes create a microenvironment that better mimics in vivo conditions by optimizing nutrient availability and reducing stress from environmental fluctuations.
In this study, we compare the effects of two different 3D culture dishes-Dish 1 (Microdrop GPS Dish) and Dish 2 (16-Well BIRR Dish)-on preimplantation genetic outcomes.
Using a sibling oocyte split design, oocytes were randomly divided after intracytoplasmic sperm injection (ICSI) and cultured in either dish, ensuring that each patient serves as their own internal control.
Embryo development was closely monitored from fertilization to blastocyst formation, to determine whether dish design has a significant impact on preimplantation embryo development.
Study Type
Interventional
Enrollment (Estimated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cairo, Egypt
- Ganin Fertility Center
-
Contact:
- Hosam Zaki, FRCOG
- Phone Number: 16270
- Email: hosamganin@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Female patients aged 35 years or younger
- A minimum of 15 mature oocytes available for ICSI
- Classified as a good prognosis patient
Exclusion Criteria:
- Cases with severe DNA fragmentation
- Patients undergoing FNA or TESE procedures
- Severe male factor infertility
- History of low or failed fertilization in previous cycles
- Any contraindications to gonadotropin stimulation
- Presence of leukocytospermia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Dish no.1
Sibling oocytes were randomly allocated for culture in Dish 1 (Microdrop GPS Dish) from the ICSI procedure until the blastocyst stage.
|
The µDrop GPS® micro-wells dish is specifically designed for oocyte and embryo handling and culture.
The sloped concave micro-well bottoms of the µDrop GPS® dish allow oocytes and embryos to settle at a central location away from the well walls.
The concave nature of the wells provides the thinnest well bottom possible, helping to reduce refraction and allow for optimal visualization.
The wells may reduce droplet collapsing/mixing, offer better orientation/optics, and reduce set-up/observation time.
|
|
Active Comparator: Dish no.2
Sibling oocytes were randomly allocated for culture in Dish 1 (16 well BIRR Dish) from the ICSI procedure until the blastocyst stage.
|
The 16-Well BIRR Dish is a high-quality 3D culture dish designed for optimal embryo handling and identification in IVF.
It features well-numbering (1-16) for clear tracking, a large labeling area, and an expanded working space for better accessibility.
Its 16 wells allow for increased wash drops and single embryo culture, reducing the number of dishes needed per IVF cycle.
Rigorously tested (MEA+, LAL, and SMA per lot), it ensures safe and efficient embryo culture.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blastocyst Development rate
Time Frame: 5 - 6 days
|
Defined as the proportion of blastocysts formed on day 5 or 6
|
5 - 6 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cleavage rate
Time Frame: 3 days
|
Defined as the proportion of cleaved embryos on day 3
|
3 days
|
|
Fertilization rate
Time Frame: 1 day
|
Defined as the proportion of fertilized oocytes
|
1 day
|
|
Blastocyst Quality rate
Time Frame: 5 - 6 days
|
Defined as the assessment of blastocyst quality according to Gardner's criteria into: good, fair or poor
|
5 - 6 days
|
|
High Quality Day 3 rate
Time Frame: 3 days
|
proportion of high quality day 3 embryos
|
3 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 1, 2025
Primary Completion (Estimated)
March 30, 2026
Study Completion (Estimated)
March 30, 2026
Study Registration Dates
First Submitted
February 26, 2025
First Submitted That Met QC Criteria
February 26, 2025
First Posted (Actual)
March 25, 2025
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
February 26, 2025
Last Verified
February 1, 2025
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- GFC-0010
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Embryo Culture
-
Sun Yat-sen UniversityNot yet recruitingEmbryo Culture | Embryo Quality | Embryo Culture Media
-
Ibn Sina HospitalBanon IVF Center Assiut, EgyptCompleted
-
Ibn Sina HospitalBanoon IVF CenterCompleted
-
Reproductive & Genetic Hospital of CITIC-XiangyaUnknown
-
IVI SevillaCompleted
-
gyn-medicum GöttingenRecruiting
-
Fertilitetscentrum ABVitrolifeCompletedBlastocyst | Human | Antioxidants | Culture Media | EmbryoSweden
-
Hung Vuong HospitalCompletedEmbryo Development | IVF | Pregnancy Rates | Embryo Culture Media | Blastocyst IVFVietnam
-
VitrolifeCompletedBlastocyst | Human | Antioxidants | Oxygen | Culture Media | EmbryoJapan
Clinical Trials on Microdrop GPS dish
-
Hillel Yaffe Medical CenterUnknown
-
Rabin Medical CenterTerminatedQuality of Life | MalnutritionIsrael
-
Clinica Universidad de Navarra, Universidad de...CompletedPostprandial Glycemia | Resistant StarchSpain
-
Sunrise Fertility CenterNot yet recruitingInfertile Patient Undergoing ICSI Procedure
-
Ryerson UniversityCompleted
-
Penn State UniversityAlliance for Potato Research and EducationCompletedCardiovascular Diseases | Type 2 Diabetes MellitusUnited States
-
Elif Güler ErginVitrolifeUnknown
-
CorinTerminatedOsteo Arthritis Knee | Total Knee Arthroplasty | Total Knee Replacement | Knee DiseaseFrance
-
Ryerson UniversityCanadian Institutes of Health Research (CIHR); Ottawa Hospital Research Institute and other collaboratorsCompletedHIV/AIDS | Health Behavior | Sexually Transmitted InfectionCanada